Currently, there are 361.49M common shares owned by the public and among those 179.87M shares have been available to trade.
The company’s stock has a 5-day price change of 1.60% and -30.02% over the past three months. LXRX shares are trading 3.29% year to date (YTD), with the 12-month market performance down to -73.97% lower. It has a 12-month low price of $0.62 and touched a high of $3.73 over the same period. LXRX has an average intraday trading volume of 4.84 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.11%, -1.51%, and -47.12% respectively.
Institutional ownership of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) shares accounts for 35.21% of the company’s 361.49M shares outstanding.
It has a market capitalization of $275.75M and a beta (3y monthly) value of 1.04. The earnings-per-share (ttm) stands at -$0.75. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.16% over the week and 13.54% over the month.
Analysts forecast that Lexicon Pharmaceuticals Inc (LXRX) will achieve an EPS of -0.12 for the current quarter, -0.12 for the next quarter and -0.5 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.17 while analysts give the company a high EPS estimate of -0.17. Comparatively, EPS for the current quarter was -0.2 a year ago. Earnings per share for the fiscal year are expected to increase by 14.05%, and 31.83% over the next financial year. EPS should grow at an annualized rate of 19.31% over the next five years, compared to 6.80% over the past 5-year period.
Looking at the support for the LXRX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on June 17, 2024, with the firm’s price target at $10. Leerink Partners coverage for the Lexicon Pharmaceuticals Inc (LXRX) stock in a research note released on April 30, 2024 offered a Outperform rating with a price target of $5. Jefferies was of a view on March 07, 2023 that the stock is Hold, while Piper Sandler gave the stock Overweight rating on August 12, 2022, issuing a price target of $10. JP Morgan on their part issued Neutral rating on January 29, 2021.
